耐利福平及耐多药结核病患者家庭接触者中高进展风险者的识别可行性
该横断面研究在8个结核高负担国家纳入284例成人耐多药结核病(MDR-TB)患者及其1016名家庭接触者(HHCs),评估接触者结核感染与发病风险。结果显示12%的接触者发现新发结核病例,72%存在结核感染,77%属于高进展风险组,但仅2%在接受预防性治疗。
要点
- MDR-TB家庭接触者中12%发现新发结核,77%为高进展风险人群。
- 仅2%的高风险接触者接受预防性治疗,提示预防治疗覆盖严重不足。
- 接触者结核感染率为72%,随年龄、检测方法和国家而异。
核心结论
- 在这些高负担国家,大多数MDR-TB家庭接触者处于结核感染和发病高风险,但极少接受常规预防性治疗。
- 亟需开展新型预防性治疗的临床试验以指导治疗政策和实践。
研究设计与样本
- 横断面研究,在8个结核高负担国家纳入成人MDR-TB病例及其家庭接触者。
- 接触者接受症状筛查、胸部X线、痰结核细菌学检查、结核感染检测(TST和IGRA)及HIV检测。
- 2015年10月至2016年4月共纳入284例MDR-TB病例的1016名家庭接触者。
主要发现
- 确诊时69%的MDR-TB病例痰抗酸杆菌涂片阳性,43%有空洞病变;研究入组时中位MDR-TB治疗时长8.8周后35%仍涂片阳性。
- 1007名接触者中121名(12%)发现新发结核:17名(2%)确诊、33名(3%)可能、71名(7%)疑似。
- 结核感染(TST或IGRA阳性)患病率为72%,随年龄、检测方法和国家而异。
- 1007名接触者中775名(77%)属于高进展风险组:102名(10%)年龄<5岁;63名(6%)年龄≥5岁且HIV阳性;610名(61%)年龄≥5岁、HIV阴性或状态未知且TBI阳性。
- 仅21名(2%)接触者正在接受预防性治疗。
关键数值与推荐
- 高进展风险定义为互斥分组:年龄<5岁、年龄≥5岁且HIV阳性、或年龄≥5岁且HIV阴性/未知但TBI阳性。
临床怎么用
- 对MDR-TB家庭接触者应系统筛查结核病和结核感染,并评估进展风险。
- 高进展风险接触者应纳入预防性治疗评估,但原文显示实际接受预防治疗者仅2%。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: We assessed multidrug-resistant tuberculosis (MDR-TB) cases and their household contacts (HHCs) to inform the development of an interventional clinical trial. METHODS: We conducted a cross-sectional study of adult MDR-TB cases and their HHCs in 8 countries with high TB burdens. HHCs underwent symptom screenings, chest radiographies, sputum TB bacteriologies, TB infection (TBI) testing (tuberculin skin test [TST] and interferon gamma release assay [IGRA]), and human immunodeficiency virus (HIV) testing. RESULTS: From October 2015 to April 2016, 1016 HHCs from 284 MDR-TB cases were enrolled. At diagnosis, 69% of MDR-TB cases were positive for acid-fast bacilli sputum smears and 43% had cavitary disease; at study entry, 35% remained smear positive after a median MDR-TB treatment duration of 8.8 weeks. There were 9 HHCs that were diagnosed with TB prior to entry and excluded. Of the remaining 1007 HHCs, 41% were male and the median age was 25 years. There were 121 (12%) HHCs that had new cases of TB identified: 17 (2%) were confirmed, 33 (3%) probable, and 71 (7%) possible TB cases. The TBI prevalence (defined as either TST or IGRA positivity) was 72% and varied by age, test used, and country. Of 1007 HHCs, 775 (77%) were considered high-risk per these mutually exclusive groups: 102 (10%) were aged <5 years; 63 (6%) were aged ≥5 and were infected with HIV; and 610 (61%) were aged ≥5 years, were negative for HIV or had an unknown HIV status, and were TBI positive. Only 21 (2%) HHCs were on preventive therapy. CONCLUSIONS: The majority of HHCs in these high-burden countries were at high risk of TB disease and infection, yet few were receiving routine preventive therapy. Trials of novel, preventive therapies are urgently needed to inform treatment policy and practice.
引用
- Gupta A, Swindells S, Kim S, et al. Feasibility of Identifying Household Contacts of Rifampin-and Multidrug-resistant Tuberculosis Cases at High Risk of Progression to Tuberculosis Disease. Clin Infect Dis. 2020. PMID: 30942853. doi:10.1093/cid/ciz235
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。